| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 183.5 | 1.0 |
| Net income | 60.1 | -64.5 |
| EPS (diluted, $ a share) | $0.58 | $-0.95 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +17628.4% |
|---|---|
| Operating margin | 38.1% |
10-Q filed with the SEC, NASDAQ: FRNM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Freenome, Inc.: key numbers
- Share price
- $10.09Close, Nov 16
- Market cap
- $1.13B
- Shares outstanding
- 111.5MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Freenome, Inc.
All →Freenome Financial Results
Freenome reported its first quarterly results as a public company, highlighted by $183.5 million in revenue following the FDA approval of its SimpleScreen CRC blood test. The company achieved GAAP net income of $60.1 million, a significant turnaround from a net loss in the prior year, and ended the quarter with $430 million in cash and marketable securities.
- Term
- Q3 2026
“Freenome made meaningful progress in its first quarter as a public company, executing on our strategic partnerships and strengthening our operating foundation.”
Aaron Elliott, Ph.D., CEO of Freenome
Freenome Product Launch
Freenome launched its SimpleScreen Lung test, a blood-based screening tool for adults aged 50-80 with a significant smoking history. The company also introduced a first-of-its-kind offering that allows eligible patients to be screened for both lung and colorectal cancer (CRC) through a single blood draw using two independently validated tests.